New ETF Book by Larry Connors - Click here to read more
ADA: Ernest N. Morial Convention Center, New Orleans, LA.
Saturday, June 6: Embargo Lifts June 6 at 9:00 a.m. CT
Oral Presentation
Abstract: 37-OR
Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
Medicine, Philadelphia, PA
Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
A 56-week Phase 3 Study"
Time: 9:00 a.m. CT
Location: Room 255
Monday, June 8: Embargo Lifts June 6 at 10:00 a.m. CT
Poster Presentation*
Abstract: 1731-P
Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
Medicine, Philadelphia, Pa.
Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
Quality of Life"
Time: 12:00 - 2:00 p.m. CT
Location: Hall E
Poster Presentation*
Abstract: 1730-P
Presenter: Samuel Klein, M.D., Washington University School of Medicine,
St. Louis, Mo.
Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
Without Worsening Psychiatric Symptoms"
Time: 12:00 - 2:00 p.m. CT
Location: Hall E
* Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
at a Poster Reception in Hall E
ENDO: Walter E. Washington Convention Center, Washington, D.C.
Friday, June 12: Embargo Lifts June 12 at 11:15 a.m. ET
Oral Presentation
Abstract: OR18-5
Presenter: F. Xavier Pi-Sunyer, M.D., M.P.H., The New York Obesity
Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y.
Title: "Combination Therapy with Naltrexone + Bupropion Causes Significant
Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals:
A Randomized Phase 3 Study Over 56 Weeks"
Time: 11:15 a.m. ET
Location: Room 152AB
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
http://www.orexigen.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.